Daxxify, with the generic name daxibotulinumtoxinA-lanm, is an FDA-approved medication used for both cosmetic and therapeutic purposes.

Johnson & Johnson is requesting U.S. FDA approval for SPRAVATO® (esketamine) as the sole treatment for adults with treatment-resistant depression.

Spesolimab, marketed under the brand name Spevigo, received FDA approval for the treatment of generalized pustular psoriasis flares in adults.

This study assessed the safety, tolerability, and pharmacokinetics of their leading lipidated IL-22 candidate, CK-0045.

Auvelity, under its generic name bupropion and dextromethorphan, has been approved by the FDA for the treatment of major depressive disorder.

The European Medicines Agency has approved Bristol Myers Squibb's application to use Opdivo (nivolumab) and Yervoy (ipilimumab) as initial treatments.

Venlafaxine received FDA approval for the treatment of major depressive disorder on December 28, 1993.

NGM Bio Secures $122 Million in Series A to Launch Primary Sclerosing Cholangitis Trial and Support Phase 2 Hyperemesis Gravidarum Study.

Vutrisiran received FDA approval on June 13, 2022, under the brand name Amvuttra.

Immutep Gets Approval for Phase I Trial of Novel LAG-3 Agonist Antibody Targeting Autoimmune Disorders.

Amoxicillin and vonoprazan, marketed under the brand name Voquezna Dual Pak, is a combination medication approved by the FDA.

Biotheryx Initiates Phase 1 Trial, Administers Initial Dose of BTX-9341, a Novel Dual Action CDK4/6 Degrader, Alone and with Other Treatments.